ARX517/JNJ-95298177

ARX517 · Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ARX517/JNJ-95298177, covering 2026-04-13 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer [Phase 1]